SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 448.47 |
| Enterprise Value ($M) | 337.44 |
| Book Value ($M) | 137.41 |
| Book Value / Share | 11.93 |
| Price / Book | 2.89 |
| NCAV ($M) | 116.94 |
| NCAV / Share | 9.00 |
| Price / NCAV | 3.84 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.28 |
| Return on Assets (ROA) | -0.64 |
| Return on Equity (ROE) | -0.78 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.09 |
| Current Ratio | 12.17 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 143.65 |
| Assets | 164.12 |
| Liabilities | 26.71 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Rtw Investments, Lp | 8.70 | ||
| 13G/A | Cormorant Asset Management, LP | 0.83 | -85.61 | |
| 13G/A | Janus Henderson Group Plc | 5.50 | -15.71 | |
| 13G/A | Great Point Partners Llc | 7.73 | 1.01 | |
| 13G | Fmr Llc | 5.63 | ||
| 13G | Casdin Capital, LLC | 6.90 | ||
| 13G/A | Redmile Group, LLC | |||
| 13G | Samsara BioCapital, L.P. | 9.99 | ||
| 13G | EcoR1 Capital, LLC | 9.99 | ||
| 13D | McMinn Rachel | 9.90 | ||
| 13D/A | Baker Bros. Advisors Lp | 4.99 | -93.14 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 326,550 | 1,886,793 | 17.31 | |
| 113,670 | 410,235 | 27.71 | |
| 315,645 | 564,047 | 55.96 | |
| 200,507 | 569,202 | 35.23 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MURA – Mural Oncology plc | NAII – Natural Alternatives International, Inc. |
| NAMS – NewAmsterdam Pharma Company N.V. | NKGN – NKGen Biotech, Inc. |
| NRIX – Nurix Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io